tiprankstipranks
Trending News
More News >
Pharming Group (PHAR)
NASDAQ:PHAR
Advertisement

Pharming Group (PHAR) Stock Statistics & Valuation Metrics

Compare
146 Followers

Total Valuation

Pharming Group has a market cap or net worth of $827.52M. The enterprise value is $744.24M.
Market Cap$827.52M
Enterprise Value$744.24M

Share Statistics

Pharming Group has 68,514,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,514,760
Owned by Insiders
Owned by Institutions

Financial Efficiency

Pharming Group’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -3.35%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.03
Return on Invested Capital (ROIC)-3.35%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee735.64K
Profits Per Employee-21.02K
Employee Count404
Asset Turnover0.74
Inventory Turnover0.64

Valuation Ratios

The current PE Ratio of Pharming Group is ―. Pharming Group’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio0.00
Price to Fair Value3.03
Price to FCF0.00
Price to Operating Cash Flow117.35
PEG Ratio

Income Statement

In the last 12 months, Pharming Group had revenue of 297.20M and earned -10.64M in profits. Earnings per share was -0.15.
Revenue297.20M
Gross Profit261.80M
Operating Income-8.62M
Pretax Income-8.20M
Net Income-10.64M
EBITDA16.32M
Earnings Per Share (EPS)-0.15

Cash Flow

In the last 12 months, operating cash flow was 31.72M and capital expenditures -913.99K, giving a free cash flow of 30.80M billion.
Operating Cash Flow31.72M
Free Cash Flow30.80M
Free Cash Flow per Share0.45

Dividends & Yields

Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.44
52-Week Price Change54.97%
50-Day Moving Average10.82
200-Day Moving Average9.30
Relative Strength Index (RSI)65.00
Average Volume (3m)7.13K

Important Dates

Pharming Group upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).
Last Earnings DateJul 31, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date

Financial Position

Pharming Group as a current ratio of 3.77, with Debt / Equity ratio of 55.67%
Current Ratio3.77
Quick Ratio3.02
Debt to Market Cap0.12
Net Debt to EBITDA3.28
Interest Coverage Ratio-0.99

Taxes

In the past 12 months, Pharming Group has paid 2.43M in taxes.
Income Tax2.43M
Effective Tax Rate-0.30

Enterprise Valuation

Pharming Group EV to EBITDA ratio is 414.07, with an EV/FCF ratio of -2.61K.
EV to Sales22.73
EV to EBITDA414.07
EV to Free Cash Flow-2.61K
EV to Operating Cash Flow-3.76K

Balance Sheet

Pharming Group has $128.73M in cash and marketable securities with $128.33M in debt, giving a net cash position of -$408.00K billion.
Cash & Marketable Securities$128.73M
Total Debt$128.33M
Net Cash-$408.00K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share$0.23

Margins

Gross margin is 88.98%, with operating margin of -2.90%, and net profit margin of -3.58%.
Gross Margin88.98%
Operating Margin-2.90%
Pretax Margin-2.76%
Net Profit Margin-3.58%
EBITDA Margin5.49%
EBIT Margin0.08%

Analyst Forecast

The average price target for Pharming Group is $39.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$39.00
Price Target Upside220.99% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast22.68%
EPS Growth Forecast42.45%

Scores

Smart Score6
AI Score70
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis